%0 Journal Article
%A Santos García, Diego
%A de Deus Fonticoba, Teresa
%A Cores, Carlos
%A Muñoz, Guillermo
%A Paz González, Jose M
%A Martínez Miró, Cristina
%A Suárez, Ester
%A Jesús, Silvia
%A Aguilar, Miquel
%A Pastor, Pau
%A Planellas, Lluis
%A Cosgaya, Marina
%A García Caldentey, Juan
%A Caballol, Nuria
%A Legarda, Inés
%A Hernández Vara, Jorge
%A Cabo, Iria
%A López Manzanares, Luis
%A González Aramburu, Isabel
%A Ávila Rivera, María A
%A Catalán, Maria J
%A Nogueira, Víctor
%A Puente, Víctor
%A Ruíz de Arcos, María
%A Borrué, Carmen
%A Solano Vila, Berta
%A Álvarez Sauco, María
%A Vela, Lydia
%A Escalante, Sonia
%A Cubo, Esther
%A Carrillo Padilla, Francisco
%A Martínez Castrillo, Juan C
%A Sánchez Alonso, Pilar
%A Alonso Losada, Maria G
%A López Ariztegui, Nuria
%A Gastón, Itziar
%A Clavero, Pedro
%A Kulisevsky, Jaime
%A Blázquez Estrada, Marta
%A Seijo, Manuel
%A Rúiz Martínez, Javier
%A Valero, Caridad
%A Kurtis, Mónica
%A de Fábregues, Oriol
%A González Ardura, Jessica
%A Ordás, Carlos
%A López Díaz, Luis M
%A McAfee, Darrian
%A Martinez-Martin, Pablo
%A Mir, Pablo
%A COPPADIS Study Group
%T Predictors of clinically significant quality of life impairment in Parkinson's disease.
%D 2021
%@ 2373-8057
%U https://hdl.handle.net/10668/27941
%X Quality of life (QOL) plays an important role in independent living in Parkinson's disease (PD) patients, being crucial to know what factors impact QoL throughout the course of the disease. Here we identified predictors of QoL impairment in PD patients from a Spanish cohort. PD patients recruited from 35 centers of Spain from the COPPADIS cohort from January 2016, to November 2017, were followed up during 2 years. Health-related QoL (HRQoL) and global QoL (GQoL) were assessed with the 39-item Parkinson's disease Questionnaire (PDQ-39) and the EUROHIS-QOL 8-item index (EUROHIS-QOL8), respectively, at baseline (V0) and at 24 months ± 1 month (V2). Clinically significant QoL impairment was defined as presenting an increase (PDQ-39SI) or decrement (EUROHIS-QOL8) at V2 ≥ 10% of the score at baseline (V0). A comparison with a control group was conducted for GQoL. GQoL did not change significantly in PD patients (N = 507; p = 0.686) or in the control group (N = 119; p = 0.192). The mean PDQ-39SI was significantly increased in PD patients (62.7 ± 8.5 years old; 58.8% males; N = 500) by 21.6% (from 16.7 ± 13 to 20.3 ± 16.4; p 
%~